Delta 8 Moonrocks 7g

According to the National Cancer Institute, delta-8-THC can be defined as:

“An analogue of tetrahydrocannabinol (THC) with antiemetic, anxiolytic, appetite-stimulating, analgesic, and neuroprotective properties. [Delta-8-THC] binds to the cannabinoid G-protein coupled receptor CB1, located in the central nervous system…This agent exhibits a lower psychotropic potency than [delta-9-THC], the primary form of THC found in cannabis.”

Delta-8-THC is chemically different from delta-9-THC by only a few atomic bonds and still offers a potent high of its own. While delta-8-THC only exists naturally in fractions of a percent, companies are finding value in concentrating esoteric cannabinoids for their unique effects and applications.

How is the delta-8-THC distillate made?
This product is made by employing a thin film distillation­–fractional distillation–of locally cultivated cannabis flower and trim. The isolation of the delta-8-THC compound in this process is accomplished through variations of temperature, vacuums, and scientific equipment to convert delta-9-THC over to delta-8-THC. This allows purification and isolation of specific cannabinoids by removing any residual solvents, impurities, and any other undesirable compounds.

This yields the most potent and refined end-product that offers the user one of the most clean, potent and unique delta-8-THC products on the legal market today. Most dried cannabis flower contains less than 1% of delta-8-THC, so getting a product that contains a substantial amount of this cannabinoid can only be done through extraction, isolation, conversion, and refinement of dried cannabis flower.

What should consumers know about delta-8 THC?
For one, delta-8-tetrahydrocannabinol has a lower psychotropic potency than its close cousin delta-9 THC, which is the most abundant cannabis constituent found in cannabis.

Second, it is known to connect to both CB1 and CB2 receptors in our bodies. A study was conducted in 1995 by Dr. Raphael Mechoulam in conjunction with Shaare Zedek Hospital, Bikur Holim Hospital, and Hebrew University in Jerusalem. In this study, delta-8 THC was administered to eight children ranging from 3 to 13 years of age with various hematologic cancers. These children had been treated with different drugs and [chemotherapy] for eight months prior to treatment with delta-8-THC. The delta-8-THC treatments started two hours before each session of chemo and continued every six hours for 24 hours. With this treatment, vomiting was completely prevented and side-effects were reported as negligible.